GlaxoSmithKline plc (GSK)
Stock Price Chart
Key Info
| Market Cap | 102.75B |
| Revenue (ttm) | 44.41B |
| Net Income (ttm) | 6.11B |
| Shares Out | 2.51B |
| EPS (ttm) | 0.99 |
| PE Ratio | 41.71 |
| Forward PE | 12.92 |
| Dividend | $1.89 |
| Dividend Yield | 4.58% |
Stock Quote
| Trading Day | Aug 3, 2020 |
| Last Price | $41.29 |
| Previous Close | $40.32 |
| Change ($) | 0.97 |
| Change (%) | 2.41% |
| Day's Open | 41.07 |
| Day's Range | 40.96 - 41.55 |
| Day's Volume | 5,256,383 |
| 52-Week Range | 31.43 - 48.25 |
More Stats
| Market Cap | 102.75B |
| Enterprise Value | 136.59B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | May 14, 2020 |
| Shares Outstanding | 2.51B |
| Float | 2.46B |
| EPS (basic) | n/a |
| EPS (diluted) | 0.99 |
| FCF / Share | 4.09 |
| Dividend | $1.89 |
| Dividend Yield | 4.58% |
| Earnings Yield | 2.40% |
| FCF Yield | 10.71% |
| Payout Ratio | 82.50% |
| Shares Short | 10.11M |
| Short Ratio | 3.61 |
| Short % of Float | n/a |
| Beta | 0.42 |
| PE Ratio | 41.71 |
| Forward PE | 12.92 |
| P/FCF Ratio | 9.34 |
| PS Ratio | 2.31 |
| PB Ratio | 5.73 |
| Revenue | 44.41B |
| Operating Income | 9.16B |
| Net Income | 6.11B |
| Free Cash Flow | 11.00B |
| Net Cash | -33.84B |
| Net Cash / Share | -13.61 |
| Gross Margin | 64.85% |
| Operating Margin | 20.62% |
| Profit Margin | 13.80% |
| FCF Margin | 24.77% |
| ROA | 7.38% |
| ROE | 63.64% |
| ROIC | 17.40% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33,754 | 30,821 | 30,186 | 27,889 | 23,923 | 23,006 | 26,505 | 26,431 | 27,387 | 28,392 |
| Revenue Growth | 9.52% | 2.1% | 8.24% | 16.58% | 3.99% | -13.2% | 0.28% | -3.49% | -3.54% | - |
| Gross Profit | 21,891 | 20,580 | 19,844 | 18,599 | 15,070 | 15,683 | 17,920 | 18,506 | 19,714 | 20,494 |
| Operating Income | 6,961 | 5,483 | 4,087 | 2,598 | 10,322 | 3,597 | 7,028 | 7,300 | 7,734 | 3,783 |
| Net Income | 4,645 | 3,623 | 1,532 | 912 | 8,422 | 2,756 | 5,436 | 4,499 | 5,208 | 1,634 |
| Shares Outstanding | 5,379 | 5,373 | 5,368 | 5,361 | 5,355 | 5,342 | 5,398 | 5,049 | 5,196 | 5,191 |
| Earnings Per Share | 1.85 | 1.46 | 0.62 | 0.37 | 3.45 | 1.13 | 2.21 | 1.80 | 2.04 | 0.64 |
| EPS Growth | 27.02% | 135.16% | 66.67% | -89.2% | 203.88% | -48.69% | 22.51% | -11.66% | 220.06% | - |
| Dividend Per Share | 2.04 | 2.16 | 2.05 | 2.77 | 2.45 | 2.65 | 2.41 | 2.48 | 2.21 | 2.00 |
| Dividend Growth | -5.43% | 5.17% | -26% | 13.16% | -7.7% | 10.09% | -2.79% | 12.34% | 10.36% | - |
| Operating Cash Flow | 9,532 | 9,747 | 8,258 | 8,106 | 4,631 | 6,284 | 8,499 | 6,048 | 7,713 | 8,631 |
| Capital Expenditures | -1,170 | -1,176 | -1,264 | -1,445 | -1,308 | -1,149 | -1,142 | -983 | -823 | -922 |
| Free Cash Flow | 8,362 | 8,571 | 6,994 | 6,661 | 3,323 | 5,135 | 7,357 | 5,065 | 6,890 | 7,709 |
| Cash & Equivalents | 4,786 | 3,958 | 3,911 | 4,986 | 5,905 | 4,407 | 5,600 | 4,265 | 5,898 | 6,241 |
| Total Debt | 30,508 | 26,064 | 17,089 | 18,790 | 16,632 | 18,784 | 18,245 | 18,302 | 14,901 | 15,100 |
| Net Cash / Debt | -25,722 | -22,106 | -13,178 | -13,804 | -10,727 | -14,377 | -12,645 | -14,037 | -9,003 | -8,859 |
| Assets | 79,692 | 58,066 | 56,381 | 59,081 | 53,446 | 40,651 | 42,086 | 41,481 | 41,080 | 42,230 |
| Liabilities | 61,335 | 54,394 | 52,892 | 54,118 | 44,568 | 35,715 | 34,274 | 34,744 | 32,253 | 32,485 |
| Book Value | 11,405 | 3,781 | -68.00 | 1,124 | 5,114 | 4,263 | 6,997 | 5,800 | 8,032 | 8,887 |
Company Profile
Company Details
| Full Name | GlaxoSmithKline plc |
| Country | United Kingdom |
| Employees | 99,437 |
| CEO | Emma N. Walmsley |
Stock Information
| Ticker Symbol | GSK |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NYSE: GSK |
Description
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; CureVac; and research collaboration with Sengenics focusing on immunology. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.